The treatment of disseminated prostate cancer with estramustine.
Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients had stable disease and two had a partial tumour response according to National Prostatic Cancer Project criteria. Twenty-five patients (58%) showed improvement in pain and urinary symptoms. Ten patients (23%) had side effects requiring cessation of therapy. These results show that estramustine has a limited role in the treatment of advanced prostate cancer and that therapy is frequently associated with intolerable side effects.
Rosenthal
M A
MA
Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Raghavan
D
D
Stuart-Harris
R
R
Ackland
S
S
Grygiel
J
J
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary; D015331:Cohort Studies; D018572:Disease-Free Survival; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine